Long-acting injections given once every two months can prevent HIV at least as well as daily pills for gay and bisexual men and transgender women, according to interim study results released May 18 by ...

A long-awaited generic version of Truvada, used for both HIV treatment and PrEP, went on the market Friday, October 2. But the wholesale cost of the new pill from Teva Pharmaceuticals – about $1,455 – ...

Most doctors agree Truvada is a boon in AIDS prevention; others express concern. July 16, 2012— -- The Food and Drug Adminstration today announced the approval of the first drug for use in people ...

Generally, Medicare Part B, Part C, and Part D plans are required to cover both generic emtricitabine/tenofovir disoproxil fumarate and brand-name Truvada for HIV prevention (PrEP) and treatment. If ...

The Biden-Harris administration announced Monday a new requirement for insurance providers to cover injectable PrEP in their policies without a co-payment for consumers. The new rule, built on ...

Gilead Sciences, Inc. GILD announced upbeat results from an interim analysis of a second late-stage study evaluating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV. The regulatory body approved lenacapavir, under the ...